Johnson & Johnson's third-quarter 2019 earnings call highlighted several positive factors that are likely to have a short-term positive impact on the stock price:

1. **Strong Financial Performance**: The company reported strong revenue and earnings growth, with operational sales growth of 3.2% and adjusted EPS increasing by 3.4% compared to the same quarter in 2018. This solid financial performance positions the company well for the future[3].

2. **Segment Growth**: All three business segments showed significant growth. Pharmaceuticals delivered 6.4% operational growth, Medical Devices saw 5.3% adjusted operational growth, and Consumer Health grew 1.3% excluding acquisitions and divestitures. Key products like TREMFYA, DARZALEX, and STELARA performed exceptionally well[3].

3. **Innovation and Pipeline**: The company made significant advancements in its pipeline, including several regulatory approvals and filings. This includes approvals for ERLEADA, STELARA, and XARELTO, which are expected to drive future growth[3].

4. **Guidance Update**: Johnson & Johnson increased its full-year sales and EPS guidance, reflecting confidence in its performance and future outlook. The updated guidance includes operational sales growth of 2.5% to 3.0% and adjusted EPS in the range of $8.84 to $8.89[3].

5. **Capital Allocation and Investment**: The company continues to invest in R&D and strategic acquisitions, reinforcing its commitment to innovation and growth. The completion of the $5 billion share repurchase program also indicates a strong capital allocation strategy[3].

Despite some challenges, such as litigation overhangs and generic/biosimilar competition, the company's overall performance and future outlook are robust.

### Conclusion

Given the strong financial results, significant segment growth, innovation milestones, and positive guidance updates, Johnson & Johnson's stock is likely to experience a positive impact in the short term.

**Rating: 1**